Shiro Fujita

Dr. Shiro Fujita

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2013 in Cancer
Verified
Journal Article
Open access
PDF file
AHAkito Hata
Akito Hata
NKNobuyuki Katakami
Nobuyuki Katakami
HYHiroshige Yoshioka
Hiroshige Yoshioka
JTJumpei Takeshita
Jumpei Takeshita
KTKosuke Tanaka
Kosuke Tanaka
YNYoshihiro Nishimura
Yoshihiro Nishimura
BACKGROUND: The secondary epidermal growth factor receptor (EGFR) mutation Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR‐tyrosine kinase inhibitor (TKI). Recent reports have demonstrated that the emergence of T790M predicts a favorable prognosis and indolent progression. However, rebiopsy to confirm T790M status can be challenging due to limited tissue availability and procedural feasibility, and little is known regarding the differences among patients with or without T790M mutation.METHODS: The study investigated 78 EGFR‐mutant patients who had undergone rebiopsy after TKI failure. The peptide nucleic acid–locked nucleic acid polymerase chain reaction clamp method was used in EGFR mutational analyses. Various patient characteristics and postprogression survivals (PPSs) after initial TKI failure were retrospectively compared in patients with and without T790M.RESULTS: The T790M mutation was identified in 4 (17%) of 24 central nervous system lesions, and in 22 (41%) of 54 other lesions (P = .0417). No other characteristics had a statistical association with T790M prevalence. Median PPS was 31.4 months in 26 patients with T790M, and 11.4 months in 52 patients without T790M (P = .0017). In the multivariate analysis, statistically significant factors for longer PPS included T790M‐positive, good performance status, and no carcinomatous meningitis.CONCLUSIONS: The emergence of T790M in central nervous system lesions was rare, compared with other lesions. Patients with T790M after TKI failure appear to have better prognoses than those without T790M. TKI rechallenge or continuous administration beyond progression may be effective after initial TKI failure. Cancer 2013;119:4325–4332. © 2013 American Cancer Society.

1 November 2015 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
AHAkito Hata
Akito Hata
NKNobuyuki Katakami
Nobuyuki Katakami
HYHiroshige Yoshioka
Hiroshige Yoshioka
RKReiko Kaji
Reiko Kaji
KMKatsuhiro Masago
Katsuhiro Masago
YYYasushi Yatabe
Yasushi Yatabe

1 June 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
SFShiro Fujita
Shiro Fujita
KMKatsuhiro Masago
Katsuhiro Masago
NKNobuyuki Katakami
Nobuyuki Katakami
YYYasushi Yatabe
Yasushi Yatabe

1 July 2010 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
YTYosuke Togashi
Yosuke Togashi
KMKatsuhiro Masago
Katsuhiro Masago
MFMasahide Fukudo
Masahide Fukudo
TTTomohiro Terada
Tomohiro Terada
SFShiro Fujita
Shiro Fujita
MMMichiaki Mishima
Michiaki Mishima
The epidermal growth factor receptor (EGFR) is recognized as an important molecular target in cancer therapy.1 x 1 Baselga, J and Arteaga, CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005; 23: 2445–2459 Crossref | PubMed | Scopus (599) | Google Scholar See all References Erlotinib is an orally active and selective tyrosine kinase inhibitor of the EGFR (EGFR-TKI) that has demonstrated antitumor activity in patients with non-small cell lung cancer (NSCLC).2 x 2 Shepherd, FA, Rodrigues Pereira, J, Ciuleanu, T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123–132 Crossref | PubMed | Scopus (4501) | Google Scholar See all References

1 January 2015 in American Journal of Roentgenology
Verified
Journal Article
Closed access
JTJumpei Takeshita
Jumpei Takeshita
KMKatsuhiro Masago
Katsuhiro Masago
RKRyoji Kato
Ryoji Kato
AHAkito Hata
Akito Hata
RKReiko Kaji
Reiko Kaji
NKNobuyuki Katakami
Nobuyuki Katakami
CT-guided lung biopsy is a well-established diagnostic method for pulmonary lesions. The aim of our study was to evaluate the diagnostic outcomes and safety profile of conventional CT-guided lung biopsies. We retrospectively analyzed the results of CT-guided lung biopsies for 750 patients to determine the diagnostic accuracy, complication rates, and independent risk factors for diagnostic failure and severe pneumothorax. Diagnostic accuracy was 92.9%. Independent risk factors for diagnostic failure were malignant lesions (odds ratio [OR], 4.20; 95% CI, 1.66-14.1; p = 0.001), lesions in the lower lobe (OR, 2.01; 95% CI, 1.17-3.47; p = 0.011), lesions 2.0 cm or smaller (OR, 2.87; 95% CI, 1.59-5.48; p < 0.001), and the presence of pneumothorax during the procedure (OR, 2.18; 95% CI, 1.27-3.78; p = 0.004). Pneumothorax requiring drainage occurred in 7% of patients. Independent risk factors for pneumothorax requiring drainage were age of 73 years or older (OR, 2.19; 95% CI, 1.21-4.05; p = 0.009), the presence of emphysema (OR, 4.29; 95% CI, 2.05-8.82; p < 0.001), benign lesions (OR, 2.33; 95% CI, 1.20-4.40; p = 0.012), supine positioning of the patient (OR, 2.61; 95% CI, 1.44-4.84; p = 0.001), and length from the pleura to the lesion of 1.5 cm or greater (OR, 3.08; 95% CI, 1.63-6.17; p < 0.001). CT-guided lung biopsy has a high diagnostic accuracy. Complication rates were acceptable and comparable to those of previous studies.

1 February 2017 in Lung Cancer
Verified
Journal Article
Open access
TKTerufumi Kato
Terufumi Kato
NMNoriyuki Masuda
Noriyuki Masuda
YNYoichi Nakanishi
Yoichi Nakanishi
MTMasashi Takahashi
Masashi Takahashi
THToyoaki Hida
Toyoaki Hida
TTTomohide Tamura
Tomohide Tamura
Drug-induced interstitial lung disease (ILD) is often associated with high mortality; however it is difficult to predict and manage. we examined the clinical findings and imaging characteristics of nivolumab induced ILD reported in the two phase II studies patients with recurrent or advanced non-small-cell lung cancer. We examined the clinical findings and imaging characteristics of all cases of ILD reported in two phase II trials of nivolumab, an anti-programmed death-1 antibody, in Japanese patients with recurrent or advanced non-small-cell lung cancer. These studies are registered with the Japan Pharmaceutical Information Center, numbers JapicCTI-132072, JapicCTI-132073. Eight (7.2%; two with squamous cell carcinoma, six with non-squamous cell carcinoma) of the 111 patients included in these two studies experienced ILD, and a causal relationship with nivolumab could not be ruled out in any of them. ILD of ≥grade 3 severity was found in four patients (3.6%), and ILD was considered a serious treatment-related adverse event in seven patients (6.3%). All of the patients who experienced ILD were male and had a history of smoking, with a median age of 65 years (range 52-78 years). In seven of the eight patients who experienced ILD, their events were rapidly resolving or resolved spontaneously or with steroid therapy; one patient died of respiratory failure without resolution of ILD, after docetaxel treatment was initiated following nivolumab discontinuation. Chest computed tomography images for the seven patients with resolving or resolution of ILD showed a pattern of organizing pneumonia or nonspecific interstitial pneumonia without traction bronchiectasis, while the patient who died had traction bronchiectasis. Although the risk factors for nivolumab-induced ILD were not identified, careful monitoring including imaging examinations is important in preventing the worsening of ILD in patients receiving nivolumab.